Advertisement

Research Article Free access | 10.1172/JCI4188

Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.

L Criscione, P Rigollier, C Batzl-Hartmann, H Rüeger, A Stricker-Krongrad, P Wyss, L Brunner, S Whitebread, Y Yamaguchi, C Gerald, R O Heurich, M W Walker, M Chiesi, W Schilling, K G Hofbauer, and N Levens

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Criscione, L. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Rigollier, P. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Batzl-Hartmann, C. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Rüeger, H. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Stricker-Krongrad, A. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Wyss, P. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Brunner, L. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Whitebread, S. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Yamaguchi, Y. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Gerald, C. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Heurich, R. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Walker, M. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Chiesi, M. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Schilling, W. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Hofbauer, K. in: PubMed | Google Scholar

Metabolic and Cardiovascular Diseases Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Leoluca.criscione@pharma,novartis.com

Find articles by Levens, N. in: PubMed | Google Scholar

Published December 15, 1998 - More info

Published in Volume 102, Issue 12 on December 15, 1998
J Clin Invest. 1998;102(12):2136–2145. https://doi.org/10.1172/JCI4188.
© 1998 The American Society for Clinical Investigation
Published December 15, 1998 - Version history
View PDF
Abstract

The new neuropeptide Y (NPY) Y5 receptor antagonist CGP 71683A displayed high affinity for the cloned rat NPY Y5 subtype, but > 1, 000-fold lower affinity for the cloned rat NPY Y1, Y2, and Y4 subtypes. In LMTK cells transfected with the human NPY Y5 receptor, CGP 71683A was without intrinsic activity and antagonized NPY-induced Ca2+ transients. CGP 71683A was given intraperitoneally (dose range 1-100 mg/kg) to a series of animal models of high hypothalamic NPY levels. In lean satiated rats CGP 71683A significantly antagonized the increase in food intake induced by intracerebroventricular injection of NPY. In 24-h fasted and streptozotocin diabetic rats CGP 71683A dose-dependently inhibited food intake. During the dark phase, CGP 71683A dose-dependently inhibited food intake in free-feeding lean rats without affecting the normal pattern of food intake or inducing taste aversion. In free-feeding lean rats, intraperitoneal administration of CGP 71683A for 28 d inhibited food intake dose-dependently with a maximum reduction observed on days 3 and 4. Despite the return of food intake to control levels, body weight and the peripheral fat mass remained significantly reduced. The data demonstrate that the NPY Y5 receptor subtype plays a role in NPY-induced food intake, but also suggest that, with chronic blockade, counterregulatory mechanisms are induced to restore appetite.

Version history
  • Version 1 (December 15, 1998): No description
Advertisement
Advertisement